Risk equalization in competitive health insurance markets: Identifying healthy individuals on the basis of multiple-year low spending

Health Serv Res. 2019 Apr;54(2):455-465. doi: 10.1111/1475-6773.13065. Epub 2018 Oct 16.

Abstract

Objective: To study the extent to which risk equalization (RE) in competitive health insurance markets can be improved by including an indicator for being healthy.

Study setting/data sources: This study is conducted in the context of the Dutch individual health insurance market. Administrative data on spending and risk characteristics (2011-2014) for the entire population (N = 16.6 m) as well as health survey data from a large sample (N = 387 k) are used.

Study design: The indicator for being healthy is low spending in three consecutive prior years. "Low spending" is defined in three ways: belonging to the bottom 60%, 70%, or 80% of the annual spending distribution. Versions of the Dutch RE model 2017 with and without the indicator are compared on individual-level payment fit and, using the survey data, group-level payment fit.

Principal findings: All three alternative models outperform the Dutch RE model 2017. However, significant unpriced risk heterogeneity remains. Compared with the 60% threshold, the 80% threshold comes with a larger improvement in fit but identifies a less selective group.

Conclusions: The performance of the RE model can be improved by adding an indicator for being healthy based on multiple-year low spending. However, risk-selection potential remains, warranting high priority to further improvement of RE.

Keywords: health insurance; health measurement; risk equalization; spending; survey data.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Financing, Personal / statistics & numerical data
  • Health Expenditures / statistics & numerical data*
  • Health Status
  • Hospitalization / economics
  • Humans
  • Insurance, Health / statistics & numerical data*
  • Mental Health Services / economics
  • Models, Economic
  • Netherlands
  • Prescription Drugs / economics
  • Risk Adjustment / methods*
  • Risk Factors

Substances

  • Prescription Drugs